Across TCGA pan-cancer cohorts, SPATA8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPATA8 data layer compared with 16 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SPATA8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA8 expression acts as an unfavorable survival marker.
LIHC, BRCA, and LGG are the cancer types where SPATA8 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.